-
公开(公告)号：US11986488B2
公开(公告)日：2024-05-21
申请号：US17089769
申请日：2020-11-05
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Idit Shachar , Hadas Lewinsky , Lihi Radomir , Anna Wiener
CPC classification number: A61K31/713 , A61K38/1774 , A61P29/00 , A61P35/02 , A61P37/06 , C07K16/2896 , A61K2039/505 , C07K2317/76
Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.
-
公开(公告)号：US20240139326A1
公开(公告)日：2024-05-02
申请号：US18258812
申请日：2021-12-23
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Nir LONDON , Efrat RESNICK , Rambabu REDDI , Adi ROGEL
CPC classification number: A61K47/55 , C09K11/07 , C09K2211/1007 , C09K2211/1014 , C09K2211/1022
Abstract: This invention is directed to substituted a methacrylamide compounds as targeted covalent protein binders and uses thereof.
-
公开(公告)号：US11959097B2
公开(公告)日：2024-04-16
申请号：US18226877
申请日：2023-07-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yaqub Hanna , Sergey Viukov , Emilie Wildschutz , Noa Novershtern , Carine Joubran , Segev Naveh Tassa , Alejandro Castrejon Aguilera , Bernardo Oldak , Shadi Tarazi , Francesco Roncato
IPC: C12N5/073
CPC classification number: C12N5/0604 , C12N2500/02 , C12N2501/115 , C12N2501/119 , C12N2501/155 , C12N2501/415 , C12N2501/91 , C12N2501/999 , C12N2506/03
Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.
-
614.发明公开公开(公告)号：US20240094224A1
公开(公告)日：2024-03-21
申请号：US18522466
申请日：2023-11-29
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Eran ELINAV , Alon SAVIDOR
IPC: G01N33/68
CPC classification number: G01N33/6893 , G01N2333/4721 , G01N2800/065 , G01N2800/26 , G01N2800/60
Abstract: Proxies for physiological states of tissue are provided. Accordingly, there are provided methods of determining host AMP landscape, establishing a profile indicative of tissue status, and identifying proxies for tissue status in AMP profiles of samples of secretions, exudates and/or excretions of the tissue. Also provided are methods for determination of disease severity and chronology.
-
公开(公告)号：US11932887B2
公开(公告)日：2024-03-19
申请号：US16940666
申请日：2020-07-28
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Asaph Aharoni , Guy Polturak
IPC: C12P13/22 , A23L3/3463 , A23L3/3526 , A23L3/3544 , A23L5/46 , C07K14/415 , C12N9/02 , C12N9/12 , C12P13/04 , C12P17/12 , C12P19/02
CPC classification number: C12P13/225 , A23L3/3463 , A23L3/3526 , A23L3/3544 , A23L5/46 , C07K14/415 , C12N9/0083 , C12N9/1205 , C12P13/04 , C12P17/12 , C12P19/02 , C12Y207/01095 , A23V2002/00 , A23V2002/00 , A23V2200/044
Abstract: The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and/or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as Mirabilis. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.
-
Patent Agency Ranking
公开(公告)号：US20240074473A1
公开(公告)日：2024-03-07
申请号：US18387165
申请日：2023-11-06
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Eldad TZAHOR , Ori PORAT-AVINOAM , Tamar Miriam Rose EIGLER-HIRSH
CPC classification number: A23L13/45 , C12N5/0658 , C12N2500/14 , C12N2501/50 , C12N2501/727 , C12N2510/00
Abstract: A method of inducing multinucleated myotube formation is provided. The method comprising contacting myogenic precursor cells from a farmed animal with an Extracellular Regulated Signaling Kinase (ERK1/2) inhibitor and/or an upregulator of intracellular Ca 2+ and/or RXR/RAR agonists, enhancing fusion and myogenic maturation.
-
617.发明授权公开(公告)号：US11884728B2
公开(公告)日：2024-01-30
申请号：US17187011
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P37/02 , A61P25/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/3955 , A61K39/39541 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K38/208 , A61K2300/00 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
公开(公告)号：US20240029819A1
公开(公告)日：2024-01-25
申请号：US18140095
申请日：2023-04-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Yifat MERBL , Assaf KACEN , Yishai LEVIN , David MORGENSTERN
Abstract: Agents binding modified antigen dependent peptides and use of same are provided. Accordingly, there is provided an agent capable of specifically binding an MHC presented peptide comprising a post translational modification (PTM), wherein the agent does not bind a peptide having the same amino acid sequence as said peptide but does not comprise said modification. Also provided are polynucleotides encoding the agent, cells expressing same and methods of use thereof. Also provided is a computer implemented method for generating a dataset of PTM on MHC bound peptides.
-
公开(公告)号：US11865184B2
公开(公告)日：2024-01-09
申请号：US17075738
申请日：2020-10-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Valery Krizhanovsky , Yossi Ovadya
IPC: A61K47/68 , A61P35/00 , A61K45/06 , C07K16/18 , C12N15/113
CPC classification number: A61K47/6843 , A61K45/06 , A61K47/6807 , A61K47/6849 , A61P35/00 , C07K16/18 , C12N15/1137 , C12N2310/14 , C12N2310/3513
Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.
-
公开(公告)号：US20230419150A1
公开(公告)日：2023-12-28
申请号：US18300629
申请日：2023-04-14
Inventor： Gil SEMO , Ziv AQUA , Oded MELAMED , Dan CHARASH , Serge ROSENBLUM , Barak DAYAN
Abstract: A quantum computing system, method and computer readable storage medium involve tuning a whispering-gallery mode optical resonator to support a resonance frequency associated with a transition frequency of an atom. Operation of a laser is controlled to cause the atom to be trapped adjacent the optical resonator and within the evanescent field portion. Based on an atom presence signal from an optical atom presence detector, an indication is provided that the atom is trapped adjacent the optical resonator. A frequency of a cooling laser is controlled to cool the atom, and the optical resonator is configured to define a closed loop-like mode including an evanescent field portion. The trapping laser is configured to cause the atom to be trapped adjacent the whispering-gallery mode resonator, and the cooling laser is configured to manipulate a state of the atom to thereby cool the atom.
-
-
-
-
-
-
-
-
-
Search Results
1003
records
(took 0.036 seconds)
